Aptevo Therapeutics Inc. (NASDAQ: APVO) reported clinical results from its RAINIER Phase 1b trial evaluating mipletamig in combination with venetoclax ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA